A15Eph A2 expression is a predictive biomarker of poorer...

Annals of Oncology 2017 / 10 Vol. 28; Iss. suppl_6

A15Eph A2 expression is a predictive biomarker of poorer activity and efficacy of FOLFIRI + cetuximab in RAS WT metastatic colorectal cancer (mCRC) patients (pts) in the CAPRI GOIM trial

Cardone, C, Paul, M C, Moreno-Viedma, V, Martini, G, Vitiello, P P, Ciardiello, D, Sforza, V, Troiani, T, Napolitano, S, Vitale, P, Zanaletti, N, Rachiglio, A M, Rizzi, D, Maiello, E, Normanno, N, Sib
How much do you like this book?
What’s the quality of the file?
Download the book for quality assessment
What’s the quality of the downloaded files?
Volume:
28
Language:
english
Journal:
Annals of Oncology
DOI:
10.1093/annonc/mdx422.014
Date:
October, 2017
File:
PDF, 68 KB
english, 2017
Conversion to is in progress
Conversion to is failed